Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$1.1 million.

  • Prime Medicine's Change in Accured Expenses fell 11805.6% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 16453.33%. This contributed to the annual value of $1.8 million for FY2024, which is 483.5% up from last year.
  • Prime Medicine's Change in Accured Expenses amounted to -$1.1 million in Q3 2025, which was down 11805.6% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Change in Accured Expenses peaked at $33.3 million during Q4 2021, and registered a low of -$33.3 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $749000.0 (2022), whereas its average is $517375.0.
  • Data for Prime Medicine's Change in Accured Expenses shows a peak YoY increase of 82630.6% (in 2025) and a maximum YoY decrease of 11805.6% (in 2025) over the last 5 years.
  • Over the past 5 years, Prime Medicine's Change in Accured Expenses (Quarter) stood at $33.3 million in 2021, then tumbled by 87.73% to $4.1 million in 2022, then crashed by 38.53% to $2.5 million in 2023, then tumbled by 105.73% to -$144000.0 in 2024, then plummeted by 643.06% to -$1.1 million in 2025.
  • Its Change in Accured Expenses stands at -$1.1 million for Q3 2025, versus $5.0 million for Q2 2025 and -$6.7 million for Q1 2025.